All In Biotech

Drug Trial Radar · NCT02092467

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS

Last checked: Nov 19, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 4,372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,372

Actual

Start

Mar 14, 2014

Primary completion

Jul 22, 2020

Study completion Jul 22, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • tofacitinibDrug

    Oral tablet, 5 mg BID

  • tofacitinibDrug

    Oral tablet, 10 mg BID

  • adalimumabBiological

    Pre-filled syringe, 40 mg subcutaneous injection, every other week

  • etanerceptBiological

    Pre-filled syringe, 50 mg subcutaneous injection, every week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)Time frame: Baseline up to last contact date (maximum up to 72 months)
  2. Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)Time frame: Baseline up to last contact date (maximum up to 72 months)

Locations

345 sites in 30 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB), Arthritis Clinical Intervention Program

    Birmingham, Alabama

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama

  • Clinical and Translational Research Center of Alabama, PC

    Tuscaloosa, Alabama

  • Southern Arizona VA Health Care System (SAVAHCS)

    Tucson, Arizona

  • University of Arizona Clinical and Translational Science Research Center

    Tucson, Arizona

  • CHI St. Vincent Medical Group Hot Springs

    Hot Springs, Arkansas

  • Arthritis And Rheumatism Associates LLC

    Jonesboro, Arkansas

  • Medvin Clinical Research

    Covina, California

  • Med Investigations, Inc.

    Fair Oaks, California

  • Talbert Medical Group

    Huntington Beach, California

  • University of California, San Diego (UCSD)- Perlman Ambulatory Clinic

    La Jolla, California

  • Valerius Medical Group And Research Center Of Greater Long Beach, Inc.

    Long Beach, California

  • ProHealth Partners

    Long Beach, California

  • Keck Medicine of USC

    Los Angeles, California

  • California Medical Research Associates Inc

    Northridge, California

  • Desert Medical Advances

    Palm Desert, California

  • Medvin Clinical Research

    Placentia, California

  • Sierra Rheumatology, Inc.

    Roseville, California

  • San Diego Arthritis Medical Clinic

    San Diego, California

  • Dr. Orrin M. Troum, Md And Medical Associates

    Santa Monica, California

  • Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center

    Torrance, California

  • Harbor UCLA Medical Center

    Torrance, California

  • Robin K. Dore M.D., Inc.

    Tustin, California

  • Medvin Clinical Research

    Van Nuys, California

  • Ventura Clinical Trials

    Ventura, California

  • Desert Valley Medical Group

    Victorville, California

  • Medvin Clinical Research

    Whittier, California

  • Arthritis Associates and Osteoporosis Center of Colorado Springs

    Colorado Springs, Colorado

  • Howard University Hospital

    Washington D.C., District of Columbia

  • RASF-Clinical Research Center, Inc

    Boca Raton, Florida

  • Bay Area Arthritis and Osteoporosis

    Brandon, Florida

  • Arthritis & Rheumatism Associates (Private Practice)

    Clearwater, Florida

  • Florida Clinical Research Group (Administrative Office)

    Clearwater, Florida

  • Dr.Robert W. Levin MDOffice of

    Clearwater, Florida

  • International Medical Research

    Daytona Beach, Florida

  • Centre for Rheumatology, Immunology and Arthritis

    Fort Lauderdale, Florida

  • University of Florida - Rheumatology at ACC

    Jacksonville, Florida

  • University of Florida College of Medicine, Jacksonville - Rheumatology Research

    Jacksonville, Florida

  • Doctors Research Institute

    Miami, Florida

  • Center for Arthritis and Rheumatic Diseases

    Miami, Florida

Showing 40 of 345 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.